Don Hess
Internal Medicine · Chickasha, OKNPI 1417984113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $401 and has fallen 78.3% since, to $87 in 2022.
Across 74 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$183
- Johnson & Johnson$143
- Bayer$114
- Sanofi-aventis U.S. LLC$95
- Sunovion Pharmaceuticals Inc.$88
- Astellas Pharma US Inc$66
- plus $386 from 18 others
What the payments were for
- Food & beverage$1,00794%
- Education$696%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $183 |
| Johnson & Johnson | 10 | $143 |
| Bayer | 7 | $114 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Sunovion Pharmaceuticals Inc. | 11 | $88 |
| Astellas Pharma US Inc | 2 | $66 |
| Amgen | 3 | $46 |
| Tersera Therapeutics LLC | 2 | $38 |
| Lilly USA, LLC | 3 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Pfizer | 2 | $32 |
| GSK | 2 | $25 |
| AstraZeneca | 2 | $23 |
| AbbVie | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,075 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 12 | $322 |
| Finasteride | 13 | $159 |
| Allopurinol | 13 | $150 |
| Donepezil Hcl | 11 | $128 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chickasha
- Steve EgwuonwuLawton$464K
- Jesse RichardsTulsa$279K
- Ryan MorganOklahoma City$235K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Ali JafryOklahoma City$33K
- Gerard McNultyTulsa$27K
- Yasir UsmanEnid$27K
- Peter LantzTulsa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.